|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/22 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| C07K 16/30 | (2006.01) |
| (11) | Number of the document | 4041763 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20789105.2 |
| Date of filing the European patent application | 2020-10-09 | |
| (97) | Date of publication of the European application | 2022-08-17 |
| (45) | Date of publication and mention of the grant of the patent | 2025-02-26 |
| (46) | Date of publication of the claims translation | 2025-06-10 |
| (86) | Number | PCT/EP2020/078427 |
| Date | 2020-10-09 |
| (87) | Number | WO 2021/069670 |
| Date | 2021-04-15 |
| (30) | Number | Date | Country code |
| 201914747 | 2019-10-11 | GB | |
| 202013180 | 2020-08-24 | GB |
| (72) |
FINLAY, William James Jonathan , GB
|
| (73) |
OTTIMO PHARMA LIMITED ,
c/o Kreston Reeves LLP
Innovation House
Ramsgate Road, Sandwich Kent CT13 9FF,
GB
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | PD1 ir VEGFR2 dvigubo surišimo agentai |
| PD1 AND VEGFR2 DUAL-BINDING AGENTS |
| Payment date | Validity (years) | Amount | |
| 2025-08-28 | 6 | 139.00 EUR |
| 2026-10-09 |